S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
S&P 500   4,273.53
DOW   33,618.88
QQQ   354.21
5 Oversold Semiconductor Stocks to Nibble On Ahead of Q3 Earnings
Is Gold Really Boring? (Ad)
3 Warren Buffett Stocks that are Moving into the Buy Zone
3 Stocks That Really, Really Need the Defense Bill to Pass
Is Gold Really Boring? (Ad)
JPMorgan to pay $75 million on claims that it enabled Jeffrey Epstein's sex trafficking operations
Stock market today: Futures climb as a miserable month for US markets nears its end. Crude nears $92
Is Gold Really Boring? (Ad)
AI Race Accelerates with Amazon's Investment In Anthropic
This Little Known Automaker May Save Your Life and Your Portfolio
ASX:TLX

Telix Pharmaceuticals (TLX) Stock Forecast, Price & News

Compare
Today's Range
N/A
50-Day Range
A$41.24
A$49.92
52-Week Range
N/A
Volume
746,789 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TLX stock logo

About Telix Pharmaceuticals (ASX:TLX) Stock

Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation (MTR) products for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company focuses on developing diagnostic and therapeutic products using MTR. Its lead products include TLX591-CDx for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX101-CDx for the diagnosis and treatment of glioblastoma (brain cancer); TLX66-CDx to treat bone marrow conditioning and rare diseases; TLX250, which is in Phase II clinical trials for the diagnosis and treatment of kidney cancer; TLX591, which is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX101 that is in Phase I/II clinical trials for the treatment of glioblastoma (brain cancer); and TLX66, which is in Phase I/IIa clinical trials for the treatment of bone marrow conditioning and rare diseases. The company also develops TLX592, a prostate cancer therapy candidate for targeted alpha therapy; TLX591-Sx, a positron emission tomography (PET) tracer that delivers PET and fluorescent (optical) imaging; and TLX599-CDx, an investigational prostate cancer imaging agent that uses single photon emission computed tomography. It has a strategic license and commercial partnership with Mauna Kea Technologies and Lightpoint Medical to develop advanced image and radio-guided surgical technologies. The company was founded in 2015 and is headquartered in North Melbourne, Australia.


TLX Stock News Headlines

The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
The "Plug and Play" Model Putting Online Giants to Shame
While e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."
TLX.AX - Telix Pharmaceuticals Limited
See More Headlines
Receive TLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Telix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
234
Year Founded
N/A

Profitability

Net Income
$-47,510,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$356.88 million
Book Value
A$0.24 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
2.31
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Christian P. Behrenbruch BEng(Hons) (Age 48)
    DPhil(Oxon), GAICD, J.D., M.B.A., MBA, Co-Founder, MD, Group CEO & Exec. Director
    Comp: $599.23k
  • Mr. Darren Smith B.Bus. (Age 58)
    FCPA, M.B.A., Group Chief Financial Officer
    Comp: $245.86k
  • Dr. Andreas Kluge M.D.
    Ph.D., Chief Medical Advisor & Director (Leave of Absence)
  • Dr. Colin Hayward FFPM
    MBBS, Group Chief Medical Officer
  • Mr. Richard Valeix M.B.A.
    Group Chief Commercial Officer
  • Dr. Michael Wheatcroft B.Sc.
    BSc(Hons), Ph.D., Ph.D., (Cantab), Chief Scientist
  • Mr. Craig Ulrick
    Chief Information Officer
  • Ms. Kyahn Williamson B.A.
    Sr. VP of Corp. Communications & Investor Relations
  • Ms. Melanie Farris (AGIA
    ACG, ACIS) BComn, B.Com., GradDip, M.A.I.C., Sr. VP of Global Governance, Risk & Compliance
  • Ms. Lena Moran-Adams L.L.B.
    Gen. Counsel













TLX Stock - Frequently Asked Questions

What other stocks do shareholders of Telix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Telix Pharmaceuticals investors own include ACADIA Pharmaceuticals (ACAD), Adverum Biotechnologies (ADVM), Aimmune Therapeutics (AIMT), ANI Pharmaceuticals (ANIP), AxoGen (AXGN), Biohaven (BHVN), bluebird bio (BLUE), Blueprint Medicines (BPMC), Calithera Biosciences (CALA) and Codexis (CDXS).

What is Telix Pharmaceuticals' stock symbol?

Telix Pharmaceuticals trades on the ASX under the ticker symbol "TLX."

How much money does Telix Pharmaceuticals make?

Telix Pharmaceuticals (ASX:TLX) has a market capitalization of $0.00 and generates $356.88 million in revenue each year. The company earns $-47,510,000.00 in net income (profit) each year or A($0.15) on an earnings per share basis.

How many employees does Telix Pharmaceuticals have?

The company employs 234 workers across the globe.

How can I contact Telix Pharmaceuticals?

Telix Pharmaceuticals' mailing address is 55 Flemington Road, Suite 401, North Melbourne, VIC 3051, Australia. The official website for the company is www.telixpharma.com. The company can be reached via phone at 61 4 4914 8448.

This page (ASX:TLX) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -